Ser303
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser303  -  KLF5 (human)

Site Information
QATYFPPsPPSSEPG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 14652801

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 2 ) , mutation of modification site ( 1 , 2 ) , phospho-antibody ( 1 , 2 ) , western blotting ( 1 , 2 )
Disease tissue studied:
breast cancer ( 2 ) , colorectal cancer ( 1 ) , colorectal carcinoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
GSK3B (human) ( 1 , 2 )
Kinases, in vitro:
GSK3B (human) ( 2 )
Treatments:
KCl ( 2 ) , lithium ( 2 ) , mutation ( 1 )

Downstream Regulation
Effects of modification on KLF5:
molecular association, regulation ( 1 , 2 ) , protein degradation ( 1 , 2 ) , ubiquitination ( 2 )
Effects of modification on biological processes:
carcinogenesis, altered ( 2 ) , transcription, inhibited ( 1 )
Induce interaction with:
FBXW7 (human) ( 1 , 2 )

References 

1

Bialkowska AB, Liu Y, Nandan MO, Yang VW (2014) A colon cancer-derived mutant of Krüppel-like factor 5 (KLF5) is resistant to degradation by glycogen synthase kinase 3β (GSK3β) and the E3 ubiquitin ligase F-box and WD repeat domain-containing 7α (FBW7α). J Biol Chem 289, 5997-6005
24398687   Curated Info

2

Zhao D, Zheng HQ, Zhou Z, Chen C (2010) The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation. Cancer Res 70, 4728-38
20484041   Curated Info